Researchers identify four cognitive biases that might be slowing drug discovery. By Courtney Andersen In an age of increasing financial and logistical pressures facing biotech and pharmaceutical companies, optimizing R&D success is a critical task. But in a commentary published last year in Drug Discovery Today, Andrew Chadwick of Tessella and Matthew Segall of Optibrium [...]
Optibrium, a provider of software solutions for drug discovery, and Tessella, the information technology and consulting services company and world leaders in digital preservation technology, published a new paper highlighting that scientists’ instincts may not always lead them to making good drug discovery decisions. The challenges of decision-making arise from the importance of multiple/conflicting criteria [...]
As pharma R&D leaders bring together their discovery and early development organizations they face tough decisions. How do you optimize project planning across a seamless R&D process? What is the right balance between risk, cost and value in the face of uncertainty? When and how should you deploy predictive technologies such as biomarkers? This webinar [...]
Tom Parke at Tessella plc highlights the advantage of designing trials that use techniques such as modelling and adaptation…read more
Once again, Tessella is proudly sponsoring this years’ Bio-IT Best Practice Awards 2010, being held at the World Trade Centre, Boston, MA, USA on April 21, 2010 in conjunction with Bio-IT’s World Conference and Expo 2010. Established in 2003, the award programme recognizes teams in industry and academia for their outstanding innovations and excellence in the [...]
Kevin Davies, Editor-in-Chief, Bio-IT and Tessella’s Dr Andrew Chadwick, Principle Consultant, Life Sciences and Health Care discuss Translational Medicine. Listen to this podcast and learn about: Effective, ethical approaches to trial design that harness incompletely validated predictive and prognostic biomarkers Ways to improve the value of image information and other rich data The tradeoffs to [...]
By Tom Parke The US Food and Drug Administration (FDA) end-of-Phase 2a (EOP2A) meeting guidance issued on the September 2009 emphasises the value of the greater use of trial simulation and alternative design strategies in the clinical trials design process. The FDA’s primary purpose of an EOP2A meeting is to select the dosing regime and [...]
BOSTON, Nov. 2, 2009 (GLOBE NEWSWIRE) — AG Mednet, the world’s largest diagnostic imaging network, announced today that more than 2000 users around the world have been credentialed to access and use its electronic diagnostic image submission platform…read more
Tessella are proud corporate sponsors of the Accelerating Development and Advancing Personalised Therapy 2009 (ADAPT 2009) being held at the Grand Hyatt, Washington DC on September 22-25 2009. This event features eight meetings with in-depth coverage of clinical trials, personalized medicine, cancer therapy, and biomarker development. This event was developed as the primary platform where these [...]
Adaptive designs are an exciting development that allows drug companies to better select doses, potentially bring novel therapies to the market faster, and provide real savings. While currently growing in popularity, Bayesian adaptive designs are still at the early adoption stage. We believe this situation will change radically and quickly when the first adaptive trial [...]
